Haplotype Analysis of Peroxisome Proliferator-activated Receptor γ Gene Polymorphisms and the Lipoprotein (a) Level
-
Chao SHEN
,
Wei FAN
,
Hui-Jian XIE
,
Ming WU
,
Zheng-Yuan ZHOU
,
Zhi-Rong GUO
,
Chen DONG
Abstract
Background: Lipoprotein (a) [Lp(a)], as an independent risk factor for cardiovascular disease, is more likely to be genetically determined according to the increasing evidence of epidemiologic and clinical studies in recent years. Peroxisome proliferator-activated receptor (PPAR)γ, the ligand-activated transcription factors, was considered as an indispensable role in the process of lipid metabolism. This study was designed to explore the associations of three single-nucleotide polymorphisms (SNPs) and the haplotypes of the peroxisome proliferator-activated receptor (PPAR)γ gene with the level of Lp(a).
Methods: Participants were recruited under the framework of the PMMJS (The Prevention of Metabolic Syndrome (MS) and Multi-metabolic Disorders in Jiangsu Province of China Study) from Apr 1999 to Jun 2004. Overall, 644 subjects were randomly selected and 3 SNPs of PPARγ gene (rs10865710, rs1805192, rs4684847) were genotyped.
Results: After adjusting for age, sex, cigarette smoking, alcohol drinking, waist circumference and body mass index, rs4684847 was significantly associated with Lp (a). The presence of the rs4684847 T allele (CT+TT) have a lower level of Lp (a) than the allele (CC) in the dominant model, mean difference was -27.30 (95%CI:-52.88~-1.73) mg/L, P<0.05. G-P-T and G-A-T haplotype were associated with lower levels of Lp (a) (P=0.0041 and<0.0001), mean difference was 49.79(95%CI:-97.52~-2.06) mg/L and 17.75(95%CI:-25.75~-9.75) mg/L.
Conclusion: PPAR gamma polymorphisms (rs10865710, rs1805192, rs4684847) and haplotypes may be the genetic risk factors for Lp (a) level.
Emerging Risk Factors Collaboration (2009). Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 302:412-23.
Sharrett AR, Ballantyne C, Coady S et al (2001). Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins AI and B, and HDL density subfractions the atherosclerosis risk in communities (ARIC) study. Circulation, 104:1108-1113.
Bennet A, Di Angelantonio E, Erqou S et al (2008).Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med, 168:598-608.
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009). Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA, 301:2331-9.
Lanktree MB, Anand SS, Yusuf S et al (2010).Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet, 3:39-46.
Xie HJ, Hai B, Wu M et al (2014). Analysis on the association between PPAR alpha/gamma polymorphisms and lipoprotein(a) in a Chinese Han population. Mol Genet Genomics, 289:981-7.
Xie H, Hai B, Guo Z et al (2014). Association between polymorphisms, haplotypes of peroxisome proliferators activated receptor a gene and the level of lipoprotein (a). Zhonghua Liu Xing Bing Xue Za Zhi, 35:787-91.
Hu XS, Guo ZR, Zhou H et al (2006). Study on the prevalence of metabolic syndrome among 35-74 year-olds in Jiangsu province. Zhonghua Liu Xing Bing Xue Za Zhi, 27:751-6.
Zhou H, Guo ZR, Yu LG et al (2010). Evidence on the applicability of the ATPIII, IDF and CDS metabolic syndrome diagnostic criteria to identify CVD and T2DM in the Chinese population from a 6.3-year cohort study in mid-eastern China. Diabetes Res Clin Pract, 90:319-25.
Azhar S (2010). Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol, 6:657-691.
Berger J, Leibowitz MD, Doebber TW et al (1999). Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects. J Biol Chem, 274:6718-25.
Frederiksen L, Brodbaek K, Fenger M et al (2002). Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab, 87:3989-92.
Gallicchio L, Kalesan B, Huang HY et al (2008). Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland. PPAR Res, 2008:276581.
Palmer LJ, Cardon LR (2005). Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet, 366:1223-34.
Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG (2012). Genetic evidence that lipoprotein (a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol, 32:1732-41.
Yu LG, Zhou ZY, Guo ZR et al (2013). Roles of peroxisome proliferator-activated receptors polymorphisms, haplotypes, levels on C-reactive protein and their interactions with abnormal body weight]. Zhonghua Liu Xing Bing Xue Za Zhi, 34:1023-9.
Zhi-Rong Guo HZ, Yi Ding, Ming Wu, Qiu Chen (2014). A Population Association Study of Ppar Alpha Polymorphisms and Haplotypes with Essential Hypertension in Chinese Population. Exp Clin Cardiol, 20:1328-1352.
Memon RA, Tecott LH, Nonogaki K et al (2000). Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology, 141:4021-31.
Cain WJ, Millar JS, Himebauch et al (2005). Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res, 46:2681-91.
Stumvoll M, Haring H (2002). The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes, 51:2341-7.
Werner C, Schirmer S, Gensch C et al (2014). The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis. Br J Pharmacol, 171:2685-703.
Enas EA, Chacko V, Senthilkumar A et al (2006). Elevated lipoprotein (a)—a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. Dis Mon, 52:5-50.
| Files | ||
| Issue | Vol 47 No 7 (2018) | |
| Section | Original Article(s) | |
| Keywords | ||
| PPAR gamma Lipoprotein a Haplotype Polymorphism | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
